Omeros (OMER) EBT Margin (2010 - 2026)

Omeros (OMER) posted EBT Margin of 518.61% for Q1 2026, up 225.65% sequentially from 412.74% in Q2 2022.

Omeros (OMER) EBT Margin (2010 - 2026) Analysis & Trends

Omeros has reported EBT Margin for 14 years, with the latest figure at 518.61% in Q1 2026.

Quarterly EBT Margin changed N/A year-over-year to 518.61% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 277.47% (down 55460.0% YoY) and the FY2020 annual result came in at 266.06%, down 11657.0% from the prior year.
EBT Margin grew to 518.61% in Q1 2026 per OMER's latest filing, from 412.74% in the prior quarter.
Over five years, EBT Margin peaked at 518.61% in Q1 2026 and troughed at 579.19% in Q1 2022.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	35.61%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	34.77%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	18.33%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-94.22%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	12.09%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	13.77%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-2.67%
10	Omeros	1.24 Bn	1.24 Bn	27.73 Mn	23.37%

Historic Data

Download Data

Date	Value
Jun 30, 2026	23.37%
Mar 31, 2026	518.61%
Jun 30, 2022	-412.74%
Mar 31, 2022	-579.19%
Dec 31, 2021	131.63%
Sep 30, 2021	-75.67%
Jun 30, 2021	-275.27%
Mar 31, 2021	-243.51%
Dec 31, 2020	-825.31%
Sep 30, 2020	-177.36%
Jun 30, 2020	-507.88%
Mar 31, 2020	-125.67%
Dec 31, 2019	-334.80%
Sep 30, 2019	-55.14%
Jun 30, 2019	-228.96%
Mar 31, 2019	-114.05%
Dec 31, 2018	-65.57%
Sep 30, 2018	-3,687.63%
Jun 30, 2018	-6,579.46%
Mar 31, 2018	-1,921.54%